Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Piet van den Ende"'
Autor:
Johannes H. Kaanders, Paul N. Span, Johan Bussink, Ilse J. Hoogsteen, Remco de Bree, Robert P. Takes, Alim Chin, Piet van den Ende, Hendrik P. Bijl, Patricia A. Doornaert, Chris H. Terhaard, Saskia E. Rademakers, Geert O. Janssens
Table S2. Eligibility criteria.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab384a10a8274b32f2a86f9bf598be8b
https://doi.org/10.1158/1078-0432.22448993.v1
https://doi.org/10.1158/1078-0432.22448993.v1
Autor:
Johannes H. Kaanders, Paul N. Span, Johan Bussink, Ilse J. Hoogsteen, Remco de Bree, Robert P. Takes, Alim Chin, Piet van den Ende, Hendrik P. Bijl, Patricia A. Doornaert, Chris H. Terhaard, Saskia E. Rademakers, Geert O. Janssens
Table S1. Participating institutions for all patients (N=345) and patients presenting with anemia(N=54).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2ce26023d6d70dc6316ea8b8c2a5e18
https://doi.org/10.1158/1078-0432.22448996
https://doi.org/10.1158/1078-0432.22448996
Autor:
Johannes H. Kaanders, Paul N. Span, Johan Bussink, Ilse J. Hoogsteen, Remco de Bree, Robert P. Takes, Alim Chin, Piet van den Ende, Hendrik P. Bijl, Patricia A. Doornaert, Chris H. Terhaard, Saskia E. Rademakers, Geert O. Janssens
Purpose: Anemia is associated with poor tumor control. It was previously observed that accelerated radiotherapy combined with carbogen breathing and nicotinamide (ARCON) can correct this adverse outcome in patients with head and neck cancer. The purp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f04f22bb151823f9ce2d362dbb97e80
https://doi.org/10.1158/1078-0432.c.6521531.v1
https://doi.org/10.1158/1078-0432.c.6521531.v1
Autor:
Johannes H. Kaanders, Paul N. Span, Johan Bussink, Ilse J. Hoogsteen, Remco de Bree, Robert P. Takes, Alim Chin, Piet van den Ende, Hendrik P. Bijl, Patricia A. Doornaert, Chris H. Terhaard, Saskia E. Rademakers, Geert O. Janssens
Table S3. Treatment delivery for all patients (N=345) and the patients presenting with anemia (N=54).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc475a6defb5bf38065fdd14a01db6b
https://doi.org/10.1158/1078-0432.22448990
https://doi.org/10.1158/1078-0432.22448990
Autor:
Hester van Boven, Piet van den Ende, Yvonne Schrage, Winette T. A. van der Graaf, A.N. Scholten, Winan J. van Houdt, Rick L. Haas, Kirsten van Langevelde, Jules Lansu
Publikováno v:
Radiotherapy and Oncology, 158, 33-39
Radiotherapy and Oncology, 158, 33-39. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 158, 33-39. Elsevier Ireland Ltd
Radiotherapy and Oncology, 158, 33-39. ELSEVIER IRELAND LTD
Radiotherapy and Oncology, 158, 33-39. Elsevier Ireland Ltd
Introduction: Oligometastatic disease and/or oligoprogression in myxoid liposarcoma(oMLS) triggers discussions on local treatment options and delay of systemic treatments. We hypothesized that satisfactory local control and postponement of systemic t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f79a0496614cf0a1e8d5ca07ac1fe43f
http://hdl.handle.net/1887/3280413
http://hdl.handle.net/1887/3280413
Autor:
A.N. Scholten, Augustinus D.G. Krol, Aisha Miah, Nina L. Jebsen, Elizabeth H. Baldini, Uta Flucke, Khin Thway, Houke M. Klomp, Piet van den Ende, Winan J. van Houdt, Hester van Boven, Erik van Werkhoven, Yvonne Schrage, Judith V.M.G. Bovée, Jos A. van der Hage, Jan F. Ubbels, Rick L. Haas, Pètra M. Braam, Johannes J. Bonenkamp, Shane Zaidi, Øyvind S. Bruland, Jules Lansu, Winette T. A. van der Graaf, Frits van Coevorden
Publikováno v:
JAMA Oncology, 7(1):205865. American Medical Association
JAMA Oncology, 7(1). American Medical Association
JAMA Oncology, 7(1). AMER MEDICAL ASSOC
Jama Oncology, 7
JAMA Oncol
JAMA oncology, 7(1), 1-8. AMER MEDICAL ASSOC
Jama Oncology, 7, 1
JAMA Oncology, 7(1). American Medical Association
JAMA Oncology, 7(1). AMER MEDICAL ASSOC
Jama Oncology, 7
JAMA Oncol
JAMA oncology, 7(1), 1-8. AMER MEDICAL ASSOC
Jama Oncology, 7, 1
Item does not contain fulltext IMPORTANCE: Currently, preoperative radiotherapy for all soft-tissue sarcomas is identical at a 50-Gy dose level, which can be associated with morbidity, particularly wound complications. The observed clinical radiosens
Autor:
Rutger J. Slegers, Jan Beckervordersandforth, Ann Hoeben, Govert Hoogland, Martijn P. G. Broen, Monique Anten, Jim T. A. Dings, Piet van den Ende, Wouter J. P. Henneman, Olaf E. M. G. Schijns
Publikováno v:
Surgical Neurology International, 13:43. Medknow Publications and Media Pvt. Ltd.
Background: Ganglioglioma (GG) and dysembryoplastic neuroepithelial tumor (DNET) belong to the group of low-grade epilepsy-associated tumors (LEAT) and are the most prevalent tumor types found in patients undergoing epilepsy surgery. Histopathologica
Autor:
Kirsten van Langevelde, Jules Lansu, Yvonne Schrage, Hester van Boven, Winan J. van Houdt, Winette T. A. van der Graaf, A.N. Scholten, Piet van den Ende, Rick L. Haas
Publikováno v:
Radiotherapy and Oncology. 163:245-245
Autor:
Johannes A. Langendijk, Ilse J. Hoogsteen, Albert J. van der Kogel, Johannes H.A.M. Kaanders, Patricia Doornaert, P.F.J.W. Rijken, Saskia E. Rademakers, Piet van den Ende, Johan Bussink, Chris H.J. Terhaard
Publikováno v:
Head & Neck. 37:171-176
BackgroundThe prognostic and predictive value of the proliferation marker Ki-67 was investigated in a randomized trial comparing accelerated radiotherapy with carbogen breathing and nicotinamide (ARCON) to accelerated radiotherapy in laryngeal carcin
Autor:
Geert O. Janssens, Remco de Bree, Piet van den Ende, Saskia E. Rademakers, I.J. Hoogsteen, Alim Chin, Johan Bussink, Johannes H.A.M. Kaanders, Patricia Doornaert, Robert P. Takes, Paul N. Span, C.H.J. Terhaard, Hendrik P. Bijl
Publikováno v:
Clinical Cancer Research, 20(5), 1345-1354. AMER ASSOC CANCER RESEARCH
Clinical Cancer Research, 20(5), 1345-1354. American Association for Cancer Research Inc.
Clinical Cancer Research, 20, 5, pp. 1345-54
Clinical Cancer Research, 20, 1345-54
Janssens, G O, Rademakers, S E, Terhaard, CH, Doornaert, P A H, Bijl, H P, van den Ende, P, Chin, A, Takes, R P, de Bree, R, Hoogsteen, I J, Bussink, J, Span, P N & Kaanders, J H 2014, ' Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer ', Clinical Cancer Research, vol. 20, no. 5, pp. 1345-1354 . https://doi.org/10.1158/1078-0432.CCR-13-1730
Clinical Cancer Research, 20(5), 1345-1354. American Association for Cancer Research Inc.
Clinical Cancer Research, 20, 5, pp. 1345-54
Clinical Cancer Research, 20, 1345-54
Janssens, G O, Rademakers, S E, Terhaard, CH, Doornaert, P A H, Bijl, H P, van den Ende, P, Chin, A, Takes, R P, de Bree, R, Hoogsteen, I J, Bussink, J, Span, P N & Kaanders, J H 2014, ' Improved Recurrence-Free Survival with ARCON for Anemic Patients with Laryngeal Cancer ', Clinical Cancer Research, vol. 20, no. 5, pp. 1345-1354 . https://doi.org/10.1158/1078-0432.CCR-13-1730
Purpose: Anemia is associated with poor tumor control. It was previously observed that accelerated radiotherapy combined with carbogen breathing and nicotinamide (ARCON) can correct this adverse outcome in patients with head and neck cancer. The purp